Dare Bioscience Inc. recently received an update from Nasdaq regarding its delisting appeal. The Nasdaq Hearings Panel has approved Dare Bioscience's modified plan to comply with the necessary requirements for continued listing. The company must demonstrate compliance by July 31, 2025, and has been granted a conditional continued listing period until August 12, 2025. Failure to meet these requirements could result in the Panel deciding to delist Dare Bioscience's common stock and suspend trading before the August deadline. The company is currently focused on executing its plan and providing necessary updates to Nasdaq to maintain its listing status.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-016374), on June 25, 2025, and is solely responsible for the information contained therein.